NCT02218697View on ClinicalTrials.gov

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

January 14, 2015

Study Completion Date

May 4, 2015

Conditions
Influenza
Interventions
BIOLOGICAL

Influsplit™ Tetra (Fluarix™ Tetra)

Intramuscular injection, 1 dose each in Control and Co-Ad groups.

BIOLOGICAL

Pneumovax™ 23

Intramuscular injection, 1 dose each in Control and Co-Ad groups.

BIOLOGICAL

Placebo (Saline)

Intramuscular injection, 1 dose each in Control and Co-Ad groups.

Trial Locations (6)

9000

GSK Investigational Site, Ghent

37100

GSK Investigational Site, Tours

37540

GSK Investigational Site, Saint-Cyr-sur-Loire

44277

GSK Investigational Site, Nantes

49000

GSK Investigational Site, Angers

53000

GSK Investigational Site, Laval

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY